Biosense Webster, Inc. has announced that FDA has cleared for marketing the CARTO® 3 System, the most advanced three-dimensional imaging technology for use by electrophysiologists in treating cardiac arrhythmias, commonly referred to as irregular heart rhythms. Atrial Fibrillation, or AFib as it`s more commonly known, is the most prevalent cardiac arrhythmia affecting between 2.3 to 5.6 million adults in the country and is the leading cause of stroke among people 65 years and older.